Rhythmic Auditory Gait Training for Parkinson's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires that participants stay on stable doses of orally-administered levodopa, so you will not need to stop taking this medication.
What data supports the effectiveness of the treatment Rhythmic Auditory Gait Training for Parkinson's Disease?
Research shows that using rhythmic auditory cues, like metronomes or music, can improve walking speed, stride length, and overall gait stability in people with Parkinson's disease. These improvements are due to the brain's ability to synchronize movement with auditory rhythms, which helps compensate for motor timing issues.12345
Is Rhythmic Auditory Gait Training safe for humans?
How does the treatment dTRAC differ from other treatments for Parkinson's disease?
The treatment dTRAC, which involves rhythmic auditory cues like metronomes and music, is unique because it uses sound to help improve walking patterns in people with Parkinson's disease. This approach leverages the brain's natural ability to synchronize movement with rhythm, potentially enhancing gait stability and dynamics more effectively than treatments without auditory cues.12479
What is the purpose of this trial?
The purpose of this research study is to determine how training to step with a metronome on both a treadmill, as well as overground, will influence the way that people with Parkinson disease walk. Using metronomes is commonly used in clinics, but the investigators will be using a combination of slow and fast frequencies to alter the way that people walk. The use of a slower frequency metronome on the treadmill is intended to help participants take larger steps. The use of a faster frequency metronome while walking overground is intended to help participants take faster steps.This will take place over 12 training sessions. Each session will be about an hour. It will include some walking tests and pictures of the brain (using MRI) before and after training.
Research Team
Mike Lewek, PT, PhD
Principal Investigator
Associate Professor
Eligibility Criteria
This trial is for people aged 50-80 with Parkinson's Disease who can walk unaided for 10 minutes and are on stable levodopa doses. They should have mild to moderate disease severity, hearing within normal range (with aids if needed), and specific walking difficulties. Excluded are those with severe heart/lung conditions, other neurological issues affecting gait, ongoing physical therapy, MRI contraindications like metal implants or claustrophobia, cognitive impairments, or past deep brain stimulation surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 12 training sessions using metronomes to influence gait, with MRI scans before and after training
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of gait and balance
Treatment Details
Interventions
- dTRAC
- Gait training without rhythmic auditory cues
- TRAC
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of North Carolina, Chapel Hill
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator